Cellectar Biosciences

$1.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-5.58%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell CLRB and other stocks, options, and ETFs commission-free!

About CLRB

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ. The listed name for CLRB is Cellectar Biosciences, Inc. Common Stock.

CEO

James V. Caruso

Employees

Headquarters

Florham Park, New Jersey

Founded

1996

Market Cap

91.83M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

3.20M

High Today

$1.97

Low Today

$1.80

Open Price

$1.93

Volume

1.58M

52 Week High

$2.98

52 Week Low

$1.01

CLRB Earnings

-$0.69

-$0.46

-$0.23

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 8, Pre-Market